Video

Dr. Offin on Targeted Agents in MET- and RET-Altered NSCLC

Michael D. Offin, MD, discusses targeted agents in MET- and RET-altered non–small cell lung cancer.

Michael D. Offin, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses targeted agents in MET- and RET-altered non—small cell lung cancer (NSCLC).

The current standard of care in MET-altered NSCLC is crizotinib (Xalkori), as outlined in the National Comprehensive Cancer Network (NCCN) guidelines. However, capmatinib, tepotinib, and savolitinib are all emerging agents in this space. Each agent had a slightly different safety profile with overall response rates (ORRs) ranging from 40% to 60%, according to data presented at the 2019 ASCO Annual Meeting.

In the RET space, the NCCN-recommended agents are somewhat toxic with suboptimal response rates, says Offin. Encouragingly, selpercatinib (formerly LOXO-292) and BLU-667 have shown greater tolerability. Although selpercatinib has shown a slightly higher ORR, both agents have been granted breakthrough therapy designations by the FDA for use in patients with RET fusion—positive NSCLC after progression on platinum-based chemotherapy.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD
Sheldon M. Feldman, MD
Laura J. Chambers, DO
Thomas Westbrook, MD